Ozark Health Ventures LLC dba Cancer Research for the Ozarks (CRO)

1 Ozark Health Ventures，LLC d/B/a Cancer Research for the Ozarks（CRO）正在提交 2这一赠款申请，因为它希望继续参与合作的努力， NCI社区肿瘤学研究计划（NCORP）的3个重点是更广泛的 4癌症预防和治疗、癌症护理提供、影像学研究和 5癌症差异 6欧扎克的癌症研究与NCI有着悠久而互利的历史 7为中部农村社区提供临床试验超过31年 8美国。自成立以来，CRO已经从密苏里州西南部发展到 9将其网络增加到15个组成站点，涵盖5个州的42个县 10个，主要是农村人口超过4，300，000。CRO将是 对于绝大多数这些试验，NCI申办的和NTCN网络试验的11个主要访问 12个病人CRO集水区的人口一般为高加索人， 13岁，比全国平均水平更穷。CRO一直是一个重要的贡献者， 14例入组涉及癌症预防和治疗、癌症护理提供的方案， 15项影像学研究和癌症差异。CRO也有许多注册， 16癌症护理交付和组织采购协议。CRO定期与NCI会面 17个注册标准和开放的CCDR协议数量。CRO有一个 18计划进一步扩大组成部分和调查人员，以确保更高的 19例入组。CRO参与了以下研究基地：联盟：成员自 2012年6月20日; NRG：自2014年合并以来的成员，以及之前的遗留团体; 21 SWOG：自1987年成立以来的成员;维克森林：自成立以来的成员 2014年22例，参与了先前癌症中心的方案; ECOG-ACRIN： 自2014年以来的23名成员和以前的遗产组。此外，CRO还 自2011年6月以来，24人参与了Mercy St. Louis的儿童肿瘤组。的 25个主要的集体优势的CRO应用程序将是巨大的支持， 26承诺两个主要组成部分，广泛的网络组成部分网站， 27质量，诚信和经验的CRO的领导和计划，并在许多 它支持的28名研究人员和合作者。 29

1 Ozark Health Ventures, LLC d/b/a Cancer Research for the Ozarks (CRO) is submitting 2 this grant application as it desires to continue to be involved with the cooperative efforts 3 of the NCI Community Oncology Research Program (NCORP) to focus on the broader 4 needs of cancer prevention and treatment, cancer care delivery, imaging studies and 5 cancer disparities. 6 Cancer Research for the Ozarks has a long and mutually beneficial history with the NCI 7 for over 31 years of offering clinical trial access to rural communities within the central 8 United States. Since its inception, CRO has grown from southwest Missouri, to 9 increasing its network to 15 component sites that incorporate 42 counties in five states 10 with a predominately rural population of more than 4,300,000. CRO would be the 11 primary access for NCI-sponsored and NTCN network trials for the vast majority of these 12 patients. The population in CRO’s catchment area is generally Caucasian, and slightly 13 older and poorer than national averages. CRO has been a significant contributor to 14 enrollments in protocols involving cancer prevention and treatment, cancer care delivery, 15 imaging studies, and cancer disparities. CRO has also had numerous registrations to 16 cancer care delivery and tissue procurement protocols. CRO routinely meets the NCI 17 criteria for enrollments and for the number of CCDR protocols it has open. CRO has a 18 plan for further expansion of components and investigators to secure even higher 19 enrollments. CRO participates with the following research bases: Alliance: member since 20 June, 2012; NRG: member since their merger in 2014 and the preceding legacy groups; 21 SWOG: member since its inception in 1987; Wake Forest: member since their inception 22 in 2014 and participated in protocols with the preceding Cancer Center; ECOG-ACRIN: 23 member since 2014 and the preceding legacy groups. In addition, CRO has been 24 involved in the Children’s Oncology Group at Mercy St. Louis since June 2011. The 25 major collective strengths of the CRO application would be the tremendous support and 26 commitment of the two primary components, the broad network of component sites, the 27 quality, integrity and experience of CRO’s leadership and the program, and the many 28 investigators and collaborators that it supports. 29